Cargando…
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metast...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/ https://www.ncbi.nlm.nih.gov/pubmed/37366384 http://dx.doi.org/10.36469/001c.75208 |
_version_ | 1785062572479741952 |
---|---|
author | Bencina, Goran Petrova, Elina Sönmez, Demet Matos Pereira, Sonia Dimitriadis, Ioannis Salomonsson, Stina |
author_facet | Bencina, Goran Petrova, Elina Sönmez, Demet Matos Pereira, Sonia Dimitriadis, Ioannis Salomonsson, Stina |
author_sort | Bencina, Goran |
collection | PubMed |
description | Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and nonmetastatic castration-resistant prostate cancer. To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). Objective: This review aimed to map HTA status, reimbursement restrictions, and patient access for 3 advanced prostate cancer indications across 23 European countries during 2011-2021. Methods: HTA, country reimbursement lists, and ESMO-MCBS scorecards were reviewed for evidence and data across 26 European countries. Results: The analysis demonstrated that only in Greece, Germany, and Sweden was there full access across all included prostate cancer treatments. Treatments available for metastatic castration-resistant prostate cancer were widely reimbursed, with both abiraterone and enzalutamide accessible in all countries. In 3 countries (Hungary, the Netherlands, and Switzerland), there was a statistically significant difference (P<.05) between status of reimbursement and ESMO-MCBS “substantial benefit” (score of 4 or 5) vs “no substantial benefit” (score <4). Conclusion: Overall, the impact of the ESMO-MCBS on reimbursement decisions in Europe is unclear, with significant variation across the countries included in this review. |
format | Online Article Text |
id | pubmed-10290826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Columbia Data Analytics, LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-102908262023-06-26 HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review Bencina, Goran Petrova, Elina Sönmez, Demet Matos Pereira, Sonia Dimitriadis, Ioannis Salomonsson, Stina J Health Econ Outcomes Res Oncology Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and nonmetastatic castration-resistant prostate cancer. To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). Objective: This review aimed to map HTA status, reimbursement restrictions, and patient access for 3 advanced prostate cancer indications across 23 European countries during 2011-2021. Methods: HTA, country reimbursement lists, and ESMO-MCBS scorecards were reviewed for evidence and data across 26 European countries. Results: The analysis demonstrated that only in Greece, Germany, and Sweden was there full access across all included prostate cancer treatments. Treatments available for metastatic castration-resistant prostate cancer were widely reimbursed, with both abiraterone and enzalutamide accessible in all countries. In 3 countries (Hungary, the Netherlands, and Switzerland), there was a statistically significant difference (P<.05) between status of reimbursement and ESMO-MCBS “substantial benefit” (score of 4 or 5) vs “no substantial benefit” (score <4). Conclusion: Overall, the impact of the ESMO-MCBS on reimbursement decisions in Europe is unclear, with significant variation across the countries included in this review. Columbia Data Analytics, LLC 2023-06-20 /pmc/articles/PMC10290826/ /pubmed/37366384 http://dx.doi.org/10.36469/001c.75208 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Bencina, Goran Petrova, Elina Sönmez, Demet Matos Pereira, Sonia Dimitriadis, Ioannis Salomonsson, Stina HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title | HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title_full | HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title_fullStr | HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title_full_unstemmed | HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title_short | HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review |
title_sort | hta and reimbursement status of metastatic hormone‑sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in europe: a patient access landscape review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/ https://www.ncbi.nlm.nih.gov/pubmed/37366384 http://dx.doi.org/10.36469/001c.75208 |
work_keys_str_mv | AT bencinagoran htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview AT petrovaelina htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview AT sonmezdemet htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview AT matospereirasonia htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview AT dimitriadisioannis htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview AT salomonssonstina htaandreimbursementstatusofmetastatichormonesensitiveprostatecancernonmetastaticcastrationresistantprostatecancerandmetastaticcastrationresistantprostatecancertreatmentsineuropeapatientaccesslandscapereview |